SF3B1 and myelodysplastic syndrome: Luspatercept is well tolerated and effective in the treatment of anemia in low-risk MDS and is approved for the treatment of transfusion-dependent low-risk MDS patients with RS and/or SF3B1 mutations (7, 71–74).